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Summary
The mechanisms of drug resistance in cancer are poorly understood. Serial analysis of gene expression (SAGE) profiling
of cisplatin-resistant and sensitive cells revealed many differentially expressed genes. Remarkably, many ECM genes were
elevated in cisplatin-resistant cells. COL6A3 was one of the most highly upregulated genes, and cultivation of cisplatin-
sensitive cells in the presence of collagen VI protein promoted resistance in vitro. Staining of ovarian tumors with collagen
VI antibodies confirmed collagen VI expression in vivo and suggested reorganization of the extracellular matrix in the
vicinity of the tumor. Furthermore, the presence of collagen VI correlated with tumor grade, an ovarian cancer prognostic
factor. These results suggest that tumor cells may directly remodel their microenvironment to increase their survival in
the presence of chemotherapeutic drugs.
Introduction Recent technological developments such as cDNA arrays
and serial analysis of gene expression (SAGE) have allowed
Resistance to anti-tumor drugs is common and represents a large-scale gene expression analysis. These techniques have
major cause of cancer death. This problem is particularly appar- provided a wealth of information on various aspects of tumori-
ent in the treatment of ovarian cancer patients with cisplatin- genesis, including cisplatin-induced changes in gene expres-
based regimens where the majority of the patients eventually sion. A number of studies have been published that identify
die of their disease with cisplatin-resistant tumors. Cisplatin potentially novel targets and pathways important in cisplatin
forms intrastrand and interstrand crosslinks in DNA, which are resistance of various cancers (Deng et al., 2002; Sakamoto et
believed to trigger cell cycle arrest and apoptosis in cancer cells al., 2001; Anderson et al., 2002; Zembutsu et al., 2002).
(Pinto and Lippard, 1985; Kartalou and Essigmann, 2001). The Cisplatin is used for the treatment of a number of malignan-
cies, including ovarian, lung, head and neck, bladder, and testic-molecular mechanisms underlying cisplatin resistance are only
partially understood and are thought to be multifactorial (Karta- ular cancers (Cohen and Lippard, 2001). It is the most efficacious
agent against ovarian cancer with initial response rates varyinglou and Essigmann, 2001). The most important molecular mech-
anisms believed to contribute to an increase in cisplatin resis- from 40%–80%. Platinum-based combination therapy, espe-
cially cisplatin/paclitaxel, offers a modest but significant im-tance include decrease in intracellular concentration of cisplatin
(Gately and Howell, 1993), interactions with inactivating mole- provement over cisplatin alone, and this regimen is now stan-
dard for women with advanced ovarian cancer (Omura et al.,cules (Godwin et al., 1992; Kasahara et al., 1991), increased
repair or tolerance to DNA adducts (Jones et al., 1994; Mamenta 1986; McGuire et al., 1996). Unfortunately, a significant fraction
of women with tumors that initially respond to chemotherapyet al., 1994; Fink et al., 1998), and altered expression of modulat-
ing genes such as p53 (Fan et al., 1994) and c-jun (Potapova eventually relapse with drug-resistant disease (Ozols and
Young, 1984). Overall, fewer than 25% of the women diagnosedet al., 1997).
S I G N I F I C A N C E
Resistance to anti-tumor drugs is common and represents a major cause of cancer death. Although many mechanisms have been
shown to be involved in resistance, the role of the microenvironment, and more specifically of the extracellular matrix, has received
less attention. Here, we show that tumor cells can remodel their microenvironment through production of collagen VI and that the
presence of collagen VI increases resistance of ovarian cells to chemotherapeutic agents. A better understanding of the tumor-
ECM interactions and signaling may reveal novel avenues for treatment of drug-resistant tumors.
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with advanced ovarian cancer will show progression-free sur-
vival after 4 years, in spite of treatment (McGuire et al., 1996).
In this context, a better understanding of cisplatin resistance
may lead to the development of novel approaches for the treat-
ment of ovarian and other cancers treated with cisplatin.
Interestingly, ECM has been suggested to provide protec-
tion against chemotherapy-induced apoptosis in small cell lung
cancer and other cancers (Sethi et al., 1999; Hazlehurst and
Dalton, 2001). It was suggested that upon activation by an ECM
ligand, integrin-mediated signal transduction, including PTK-
dependent mechanisms, can provide protection against apo-
ptosis. In the microenvironment of the tumor, cancer cells and
stroma cells interact to create favorable ECM interactions. The
key components of the ECM in chemotherapy resistance and
the mechanisms of ECM reorganization are not understood (De-
Clerck, 2000). In addition, it is currently unclear whether the
stroma or the cancer cells themselves can produce the ECM
components necessary for remodeling.
It is clear that a better understanding of the molecular mech-
anisms leading to cisplatin resistance may provide targets for
agents that may modulate cisplatin resistance and increase the
effectiveness of cisplatin chemotherapy. In order to address
this question, we have generated ovarian cancer cell lines resis-
tant to cisplatin through intermittent exposure to cisplatin, con-
ditions similar to the development of cisplatin resistance in pa-
tients. Using SAGE, we report the identification of many genes
differentially expressed as a result of cisplatin resistance. Genes
encoding ECM proteins were particularly striking, and we show
that collagen VI, an ECM protein that has been ascribed growth
factor-like properties, is highly upregulated in cisplatin-resistant
cells and can significantly increase resistance to cisplatin in
ovarian cancer cells in vitro. Importantly, staining of ovarian
tumors with a collagen VI antibody reveals areas of high collagen
VI concentration in the microenvironment of the tumor cells and
shows that collagen VI is expressed by the tumor cells. Collagen
VI RNA levels in tumors were associated with tumor grade, a
prognosis factor in ovarian cancer. These findings suggest that
tumor cells can modulate their microenvironment to favor sur-
vival in the presence of chemotherapeutic drugs. Figure 1. Characterization of cisplatin-resistant clones ACRP and ACR6 by
clonogenic assays
Results A: Surviving colonies of a typical experiment are shown for the cell lines
A2780, ACR6, and ACRP following treatment with 10 or 15 M cisplatin.
B: Colonies from (A) were counted and plotted for the various lines at 10Generation of cisplatin-resistant lines
uM and 15 uM cisplatin.In order to obtain perfectly matched cisplatin-sensitive and
-resistant ovarian cancer cells, we generated these lines in our
laboratory. In addition, rather than passaging the lines continu-
ally in high concentrations of cisplatin, the parental A2780 ovar-
tion, respectively. Through a series of clonogenic assays withian cancer line was treated intermittently with cisplatin for 24
a wide range of drug concentration, it was determined that thehr and then expanded in the absence of the drug. We reasoned
cisplatin IC50 for A2780 and ACRP were 0.75 M and 3 M,that this more closely resembles the treatment leading to the
respectively (data not shown). Finally, we tested whether cis-formation of cisplatin-resistant tumors in patients. Of the ten
platin resistance was associated with crossresistance to otherclones obtained after three rounds of cisplatin selection, two of
chemotherapeutic agents. Similar experiments were thus re-the clones, ACR6 and ACRP, exhibited significant increase in
peated in order to evaluate the resistance of A2780 and ACRPcisplatin survival compared to the A2780 parental line. Indeed,
to doxorubicin and taxol. We found that ACRP cells were moreafter treatment with 10 M cisplatin, the ACRP line yielded
resistant to both these agents, although the resistance to taxolapproximately 30 times more colonies compared to A2780 (Fig-
was less pronounced (see Supplemental Data at http://ures 1A and 1B). ACR6 had a more modest resistance level
www.cancercell.org/cgi/content/full/3/4/377/DC1).with approximately 3-fold increase in surviving colonies. Al-
We believed the ACRP cell line to be particularly interestingthough the number of colonies was lower overall, this trend was
for many reasons. First, it was selected from a pool of clonessimilar following 15 M cisplatin treatment, where ACR6 and
ACRP exhibited 3-fold and 60-fold increases in colony forma- and subsequently reselected with cisplatin, in a fashion similar
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to the development of resistance in vivo. Secondly, ACRP exhib- were measured in A2780, ACR6, and ACRP. RT-PCR confirmed
the levels of upregulation obtained by SAGE (Figure 3A). DCNited a much higher level of cisplatin resistance than ACR6.
Finally, ACRP acquired co-resistance to other agents, as is often and PAPSS were also found upregulated in ACR6. Among the
genes downregulated in cisplatin-resistant cells, FADS, FLNA,observed in tumors from patients undergoing chemotherapy.
and CRABP were selected for validation. These genes were
indeed found downregulated in ACRP and ACR6 compared toIdentification of genes differentially
expressed using SAGE A2780 (Figure 3B).
In an attempt to identify molecular determinants underlying cis-
platin resistance, we used SAGE to obtain gene expression Collagen VI increases cisplatin resistance
Because two different types of collagen were found upregulatedprofiles of A2780 and ACRP. SAGE is a powerful quantitative
technique that allows determination of gene expression profiles in cisplatin-resistant cells (Table 1) and because collagens had
previously been found generally upregulated in advanced ovar-in tissues of interest (Saha et al., 2002; Velculescu et al., 1995).
The SAGE libraries were constructed and over 30,000 tags were ian cancer (Ismail et al., 2000; Hough et al., 2000), we hypothe-
sized that collagen by itself might play a role in providing drugobtained for each of the two libraries. After correction for se-
quencing errors (Zhang et al., 1997), a total of approximately resistance to these tumors. This is particularly interesting, as
little is known about the involvement of collagens in cancer drug15,000 unique genes were identified in each of the libraries. The
libraries were clearly similar: a scatter plot of the tag frequency resistance. COL6A3 was one of only eight genes to be found
upregulated in ACRP with p 0.001. Human collagen VI proteinin the libraries demonstrated a high degree of similarity with a
Pearson correlation coefficient of 0.75 (Figure 2A). However, in was therefore used to coat tissue culture dishes to directly test
its effects on cisplatin resistance. A2780 parental cells grownspite of the high degree of similarity, many genes were signifi-
cantly (p  0.05) differentially expressed between these lines on collagen VI were found to be significantly more resistant to
cisplatin than cells grown on untreated culture dishes at alland are indicated as solid diamonds in the scatter plot (Fig-
ure 2A). cisplatin concentrations tested (Figure 4A). This phenomenon
did not depend on the concentration of serum in the mediumGenes differentially expressed between A2780 and ACRP
(p  0.05) are shown in Table 1 and Table 2. Genes with a high and was observed with media containing 1% or 10% serum
during cisplatin treatment. Although plating on collagen I pro-level confidence differential expression (p 0.001) are indicated
in italics in these tables. All the genes listed were divided into vided an increase in colony-forming ability in the absence of
cisplatin, this phenomenon was not sufficient to explain thefunctional categories in an attempt to clarify the possible mecha-
nisms behind ACRP’s drug resistance (Figure 2B). A large num- approximately 15-fold increase observed in cisplatin resistance
at 1.0 M on collagen VI in 1% serum (Figure 4B). While weber of both the down and upregulated genes fell into three main
functional categories. These are cell cycle control/apoptosis observed the same pattern of resistance at higher concentra-
tions of cisplatin, these experiments were performed at concen-(cyclin I, growth arrest-specific 2 like 1), metabolism/energy
homeostasis (NADH dehydrogenase subunit 1, creatine kinase), trations varying between 0.5 and 2 M, a range more likely to
be physiologically relevant and close to the IC50 of A2780 (0.75and DNA repair/modification enzymes (RAD23 homolog B, DNA
polymerase 1). Interestingly, the SAGE data exhibited evidence M). In addition, while collagen I provided some protection
against cisplatin treatment, the effect was much more pro-of known mechanisms of chemotherapeutic resistance such as
cell cycle control and DNA repair, but five genes involved in nounced with collagen VI, especially at higher cisplatin concen-
trations. The cisplatin resistance was not simply due to in-ECM structure and/or function were also found upregulated in
ACRP. The involvement of ECM proteins in anticancer drug creased proliferation of the cells in the presence of collagen VI.
Indeed, cells plated on collagens without cisplatin treatmentresistance has not been extensively studied. Four of the genes
encode protein products that are secreted into the ECM (colla- did not exhibit increased proliferation as measured by MTS
(Figure 4C). On the other hand, the resistance level of ACRP,gen XI, collagen VI, cartilage linking protein 1, decorin) and
PAPSS functions in posttranslational modification (sulfate ester- a cell line overexpressing collagen VI, was not significantly af-
fected by the presence of collagen VI (data not shown). Thisification of polysaccharides) of proteoglycans of the ECM. The
downregulated genes included some genes encoding proteins result with ACRP cells shows that the increase of cisplatin resis-
tance does not represent a nonspecific effect that occurs in theinvolved in chromatin structure/remodeling (chromodomain hel-
icase DNA binding protein and H1 histone), as well as products presence of collagen regardless of the cell tested but is most
pronounced in cisplatin-sensitive cells expressing low levels ofinvolved in protein synthesis (Figure 2B, Table 2).
collagen VI. A2780 cells were indeed shown to express and
secrete less collagen VI protein compared to ACRP (see Supple-Validation of differentially expressed genes
Many genes identified by SAGE as differentially expressed were mental Data on Cancer Cell website).
selected for validation by semi-quantitative real-time RT-PCR
using the SYBR green I assay. The validation process was also Collagen VI is expressed in primary ovarian tumors
The previous results demonstrate that collagen VI can be ex-an opportunity to extend the SAGE finding to ACR6, a cell line
also resistant to cisplatin but to a much lesser degree. Because pressed by ovarian tumor cells in vitro and promotes cisplatin
resistance. In order to assess collagen VI expression in ovarianmany genes of the ECM appeared upregulated in cisplatin-
resistant ACRP and because of the lack of precedent for the tumors in vivo, a panel of RNAs obtained from microdissected
ovarian tumors (Hough et al., 2001) as well as our ovarian tumorinvolvement of these genes in cisplatin resistance, they were
chosen for validation by semi-quantitative real-time RT-PCR. microarray (Rangel et al., 2003) were analyzed by semi-quantita-
tive real-time RT-PCR and immunofluorescence. Semi-quantita-Primers were designed for RT-PCR of COL6A3, COL11A1, DCN,
CRTL1, and PAPSS, and the expression levels of these genes tive RT-PCR analysis of collagen VI in the microdissected ovar-
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Figure 2. Many genes are differentially expressed
between A2780 and the cisplatin-resistant cell
line ACRP
A: Tag frequency scatter plot of ACRP versus
A2780. The frequency of each tag (per 30,000)
is plotted on a logarithmic scale. Tags that are
significantly differentially expressed in ACRP
compared to A2780 (p  0.05) are indicated in
black. Some diamonds may represent multiple
tags that are expressed at identical levels.
B: Genes differentially expressed between A2780
and ACRP are grouped into main functional cat-
egories. The number of genes in each category
is indicated.
ian tumors of various subtypes confirmed the expression of differentiated tumors expressed COL6A3 above an arbitrary
level of 325-fold (dotted line on Figure 5B) while none of thethis gene in vivo. The levels of expression were highly and
consistently elevated in all four major subtypes of ovarian cancer more differentiated tumors expressed this gene above that level.
This correlation was particularly intriguing considering that ovar-(serous, endometrioid, mucinous, and clear cell) when com-
pared to cultures of human ovarian surface epithelial cells (Fig- ian tumor grade has previously been associated with response
to therapy and overall patient survival (Ozols et al., 1980; Makarure 5A). Interestingly, the levels of COL6A3 expression in tumors
were comparable to the levels observed in the ACRP cell line. et al., 1995; Shimizu et al., 1998).
In order to show that collagen VI was present at the proteinCOL6A3 levels were most variable within the serous subtype,
which led us to wonder whether COL6A3 levels might be associ- level in primary ovarian tumors, our ovarian tissue array was
stained using a collagen VI antibody and Cy5-conjugated sec-ated with other properties of these tumors. Interestingly, we
found that the expression of COL6A3 was associated with the ondary antibody. Many of the tumors studied were positive for
collagen VI. In these tumors, cytoplasmic staining of the tumorgrade of tumors. Highly or moderately differentiated (low grade)
tumors expressed lower levels of COL6A3 on average than cells as well as extracellular staining in their immediate vicinity
were frequently observed (Figures 6A and 6B). The stainingpoorly differentiated (high grade) tumors (p  0.018) (Figure
5). This is particularly apparent as almost half of the poorly sometimes extended somewhat into the stroma of the tumors
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Table 1. Genes upregulated in cisplatin-resistant cells
Transcript Taga Foldb Gene Location Accession
ACCCTTGGCC 22.6 NADH dehydrogenase subunit 1 (MTND1) Mito XM_166858
CAAAATCAGG 15.0 cyclin I (CCNI) 4q13 NM_006835
ATTTTTTCAA 14.0 3-phosphoadenosine 5-phosphosulfate synthase 1 (PAPSS1) 4q24 NM_005443
GCAAAAGCTT 13.0 collagen, type XI, alpha 1 (COL11A1) 1p21 NM_001854
CACTACTCAC 12.9 cytochrome b gene (MTCYB) Mito AF172368
ACTAACACCC 12.6 NADH dehydrogenase subunit 2 (MTND2) Mito AF014899
ACTTTAGATG 12.0 collagen, type VI, alpha 3 (COL6A3) 2q37 NM_004369
ATTGTGAGGC 11.0 FLJ31373 9q31 AK024090
GCCCGCAAGC 11.0 bromodomain-containing 4 (BRD4) 19p13 NM_014299
CCTCAGGATA 10.3 NADH dehydrogenase subunit 6 (MTND6) Mito AF510390
CTAAGACTTC 10.2 mitochondrial match Mito
AAGATGAGGG 10.0 small nuclear ribonucleoprotein polypeptide B (SNRPB2) 20p11 NM_003092
GTAGCAGGTG 10.0 mannose 6 phosphate receptor binding protein (TIP47) 19p13.3 XM_012862
GTTTGGCAGT 10.0 hypothetical protein H41 (H41) 3q22.2 AF103803
CATTTGTAAT 9.5 cytochrome c oxidase subunit I (MTCO1) Mito AF382012
AAGCCTTGCT 9.0 HT027 (FLJ20886) 17q25.3 AF246238
CTCACTTCTT 9.0 EST: clone 25076 3 AF131807
CTTGACACAC 9.0 eukaryotic translation initiation factor 5 (EIF5) 14q32 NM_001969
GAAGTTATAA 8.9 paternally expressed 10 (PEG10) 7q21 NM_015068
ATTTGAGAAG 7.8 RAD23 homolog B (RAD23B) 9q31 NM_002874
CAATAGCTTA 7.5 cartilage linking protein 1 (CRTL1) 5q14 U43328
GCAAGCCAAC 7.5 NADH dehydrogenase subunit 4 (MTND4) Mito NC_001807
CACCTAATTG 7.2 ATP synthase 6 (MATP6) Mito AF368271
AAAAGATACT 7.0 CBP/p300-interacting transactivator 2 (CITED2) 6q23 NM_006079
AAGTTTCCAA 7.0 protein phosphatase 4 catalytic subunit (PPP4C) 16p12 NM_002720
ACAGCTAATT 7.0 EUROIMAGE 39515 mRNA X AL079283
ACTTATTATG 7.0 decorin (DCN) 12q13.2 NM_001920
CGGTCTTATG 7.0 dual-specificity tyr-phospho regulated kinase 1A (DYRK1A) 21q22 NM_130436
CTCAATGGCG 7.0 sal-like 4 (SALL4) 20q13 NM_020436
GCCAACCTCC 7.0 NADH dehydrogenase subunit 1 (MTND1) Mito XM_166858
TCACAATACA 7.0 cyclophilin D (PPID) 4q31 NM_005038
TGAAGTAACA 7.0 putative translation initiation factor (SUI1) 19p13 NM_005801
TGCAATAAGC 7.0 DKFZp434I0835 ? AL122072
TGTTAGCAAA 7.0 EST 11p13 Z40582
a Tags in bold have a p  0.001.
b The listed fold values are relative to A2780.
but the stromal areas and the normal ovarian surface epithelium resistant or acquire resistance during treatment. The mecha-
nisms of development of cisplatin resistance in vivo are poorlywere negative. This yielded a pattern of uniform staining in the
tumor areas with collagen VI gradually decreasing away from understood. Several models have been proposed but it remains
unclear which process is sufficient for the development of drug-the tumor cells to become undetectable in stromal area (Figures
6A and 6B). This pattern of staining is consistent with tumor resistant tumors in patients and whether different tumors can
use different strategies to develop resistance. Many studiescell secretion of collagen VI, leading to a remodeling of the ECM
in the microenvironment of the tumors. Consistent with our have identified differential response of resistant cells to cisplatin
challenge but little work has been done to identify intrinsic differ-semi-quantitative real-time RT-PCR findings, some of the tu-
mors exhibited little or no detectable collagen VI staining (Figure ences in cisplatin-resistant cells in the absence of drug. We
reasoned that the resistant cells must possess inherent differ-6C). Overall, 52% of the serous ovarian tumors exhibited posi-
tive collagen VI staining as measured by immunofluorescence. ences in gene expression and molecular circuitry, even in the
absence of drugs, that will allow them to respond more efficientlyHighly differentiated, low grade tumors frequently did not ex-
press collagen VI, but in contrast to our observation using RT- to cisplatin exposure. In addition, we chose to generate a cis-
platin resistance model using repeated short exposures to cis-PCR, no correlation between collagen VI protein and grade was
observed. This could be due to the difficulties associated with platin, a situation similar to the type of natural selection that
occurs in patients during chemotherapy. The cell lines gener-quantification of immunofluorescence results. It will be impor-
tant to study collagen VI expression in a large cohort of patients ated exhibited significant increases in survival to cisplatin chal-
lenges.treated with cisplatin in order to tease out possible differences
in chemotherapy response associated with collagen VI expres- Because we sought highly quantitative gene expression pro-
files, we chose SAGE to study our cisplatin resistance model.sion.
Of the approximately 18,000 tags representing transcripts ex-
pressed at levels higher than 0.01%, only 67 were found to beDiscussion
significantly different (p  0.05). When a p value of 0.001 was
used, only 16 genes were differentially expressed (see TablesPlatinum-based combination therapy is standard chemotherapy
for ovarian cancer. Unfortunately, most tumors are intrinsically 1 and 2). These results show that, despite exhibiting a significant
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Table 2. Genes downregulated in cisplatin-resistant cells
Transcript Taga Foldb Gene Location Accession
TTGGTGAAGG 95.0 thymosin, beta 4 (TMSB4X) Xq21.3 NM_021109
CTGTTGGCAT 22.0 ribosomal protein L21 (RPL21) 10q26.13 NM_000982
GTGAGCCCAT 18.0 heat shock 90kD protein 1, beta (HSPCB) 6p12 NM_007355
TGGAGAATGT 14.0 integrin beta-1 CD29; Fibronectin receptor (ITGB1) 10p11.2 NM_002211
TTACTTCCCC 14.0 fatty acid desaturase 2 (FADS2) 11q12 NM_004265
CTCACCGCCC 12.0 cellular retinoic acid-binding protein 2 (CRABP2) 1q21.3 NM_001878
GAATGAAGCT 12.0 ESTs ? AA725362
TGAAGTTATA 12.0 integrin beta-1 CD29; Fibronectin receptor (ITGB1) 10p11.2 NM_002211
ATGGCGATCT 10.0 ribosomal protein S24 (RPS24) 10q22 NM_001026
CTGTCCTTGT 10.0 thioredoxin related protein (MGC3178) 6p25.2 NM_030810
GAAATACAGT 10.0 Cathepsin D (CTSD ) 11p15.5 NM_001909
GCACCTCAGC 10.0 over-expressed breast tumor protein (OBTP) 6p21.3 NM_017601
TACGTACTGC 10.0 translocase inner mito memb. 13 homolog (TIMM13) 19p13.3 NM_012458
CACCCCTGAT 9.0 creatine kinase, brain (CKB) 14q32 L47647
CCTGAACTGG 9.0 chromodomain helicase DNA binding protein 4 (CHD4) 12p13 NM_001273
CGGCTGAATT 9.0 phosphogluconate dehydrogenase (PGD) 1p36 BC000368
GCCCAAGGAC 9.0 filamin A, alpha (FLNA) Xq28 XM_048404
GCCCCTGCCT 9.0 aminopeptidase B (RNPEP) 1q32 XM_036500
TCTGGTTTGT 9.0 transmembrane trafficking protein (TMP21) 14q24 NM_006827
TGCTGCCCTG 9.0 v-myb oncogene homolog-like 2 (MYBL2) 20q13.1 NM_002466
CTTAAGGATT 8.5 PAI-1 mRNA-binding protein (PAI-RBP1) 1p31-p22 NM_015640
CAGGCCCCAC 8.0 S100 calcium-binding protein A11 (S100A11) 1q21 NM_005620
GGGTCTGCGG 8.0 copine VII (CPNE7) 16q24.3 NM_014427
TCTTGATATT 8.0 collagen, type V, alpha 2 (COL5A2) 2q14-q32 NM_000393
TGTGTGTTTG 8.0 H1 histone family, member 0 (H1F0) 22q13.1 BC000145
CCCACGGTTA 7.0 methionine-tRNA synthetase (MARS) 12q13.2 NM_004990
CTGTGCCCAG 7.0 ribosomal protein L30 (RPL30) 8q22 NM_000989
GCACAATGGG 7.0 Growth arrest-specific 2 like 1 (GAS2L1) 22q12.2 NM_006478
GGGCGGGGGC 7.0 DNA polymerase delta 1, (POLD1) 19q13.3 NM_002691
GGTGAGACAC 7.0 solute carrier family 25 (SLC25A6) Xp22;Yp XM_114724
TACTGGCCGC 7.0 ESTs 6q22.33 BG168419
TCCCCGTACC 7.0 No matches
TTTGTCTGCT 7.0 No matches
a Tags in bold have a p  0.001.
b The listed fold values are relative to A2780.
difference in cisplatin response, these cell lines have very similar 1997). Collagen VI has been shown to bind to several proteins of
the ECM, including decorin (Wiberg et al., 2001), another proteinexpression profiles. Importantly, many genes identified by SAGE
were confirmed by semi-quantitative real-time RT-PCR and ex- identified as upregulated in our study (Table 1). Collagen VI-
decorin interactions may be important for the increased drughibited similar fold differences as found by SAGE.
Among the genes with significantly altered expression pat- resistance that we observed.
When parental cells were exposed to purified collagen VI, weterns between cisplatin-sensitive and cisplatin-resistant cells,
many were predicted to encode proteins involved in ECM orga- observed a specific and significant increase in cisplatin survival
(Figure 4). Collagen VI was recently shown to inhibit apoptosisnization and/or signaling. This is particularly interesting since
many collagen genes, including COL6A3, have previously been through reduction of Bax, and this effect was not observed with
collagen I (Ruhl et al., 1999). There is therefore a precedent forshown to be upregulated in ovarian cancer (Ismail et al., 2000).
Collagen IV has been reported increased in the tumor microenvi- collagen VI to affect signaling pathways important in survival
and proliferation. It is still unclear whether these effects areronment and has been hypothesized to be important for ECM-
tumor interactions (Lohi et al., 1998; Sethi et al., 1999). In addi- mediated through the integrins or through other receptors. It
will be important to determine the exact molecular pathwaystion, the presence of ECM components and related signaling
can reduce cell susceptibility to apoptosis and might be respon- affected by collagen VI that influence the response of ovarian
cancer cells to cisplatin. ECM proteins, and in particular collagensible for increased chemotherapeutic drug resistance in small
cell lung cancer (Sethi et al., 1999; Rintoul and Sethi, 2001). VI, may increase cisplatin resistance through their ability to
regulate chemotherapy-induced apoptosis.From our study, one of the most highly upregulated genes in
cisplatin-resistant cells is COL6A3, a gene encoding a chain of It is a well-accepted idea that the tumor microenvironment,
and in particular the ECM, can have a profound effect on tumorcollagen VI, a microfibrillar collagen that contains subdomains
similar to the type A domains of the von Willebrand factor, cell sensitivity to cytotoxic stresses (Sutherland and Durand,
1972; Dalton, 1999; Sethi et al., 1999). Two forms of microenvi-fibronectin type 3 domains, and a C-terminal Kunitz-type mod-
ule (Mayer et al., 1994). Collagen VI is believed to be involved ronment-tumor interactions that can affect tumor cell sensitivity
have been described: the interaction with soluble factors se-in cell anchoring as well as signaling through interactions with
integrins (Pfaff et al., 1993) and possibly other receptors such creted by stromal cells and the direct interaction with ECM. A
classic example of the first scenario is the secretion of IL-6 byas NG2 (Nishiyama and Stallcup, 1993) and DDR1/2 (Vogel et al.,
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Figure 3. Semi-quantitative real-time RT-PCR validation of differentially ex-
pressed genes
A: Validation of selected upregulated genes in ACRP. The y axis represents
the fold upregulation of the indicated genes in the cisplatin-resistant cell
lines compared to parental A2780 cells.
B: Validation of selected downregulated genes in ACRP. The y axis repre-
sents the level of expression of the indicated genes in the cisplatin-resistant Figure 4. Collagen VI protein specifically increases cisplatin resistance of
cell lines ACR6 and ACRP compared to parental A2780 cells. parental ovarian cancer cell line A2780
A: A2780 and ACRP cells were plated in 12-well dishes previously coated with
collagen I, collagen VI, or left uncoated. Typical wells of A2780 clonogenic
assays after treatment with the indicated concentrations of cisplatin for 24
hr are shown.stromal cells in the bone marrow that can affect drug response
B: The results of a clonogenic assay of A2780 cells plated on various collagen
in myeloma cells (Lotem and Sachs, 1992). The second situation substrates after cisplatin treatment (0, 0.5, 0.75, 1.0 M) are shown. Number
is exemplified by a large number of studies demonstrating that of surviving colonies are indicated.
C: MTS proliferation assays were performed on cells plated on collagen IECM and adhesion can significantly increase the resistance of
(I), collagen VI (VI), or left uncoated (U).tumor cells to anticancer agents (St Croix et al., 1996; Sethi et
al., 1999; Damiano et al., 1999). In this report, we show that
tumor cells themselves may play an active role in remodeling
their microenvironment in order to maximize their survival in the of a particular tumor is a result of a combination of many factors
presence of cytotoxic agents. In addition, in such circum- interacting in complex fashion. For example, increased drug
stances, tumors expressing ECM proteins might have the ability inactivation, increased DNA repair, and other factors may all
to form drug-resistant distant metastases by taking advantage have additive or synergistic roles in cisplatin drug resistance.
of optimal ECM-tumor cell interactions. It will be important to perform detailed studies on the tumors
The fact that secreted factors may contribute to chemother- of patients that respond to various degrees to chemotherapy
apeutic drug resistance has interesting clinical implications. In in order to sort out these issues. The generation of mouse
this scenario, only a fraction of the tumor population would models of drug resistance may also help to resolve these ques-
need to secrete appropriate factors, creating a field effect. This tions.
mechanism would favor an increase in drug resistance in exist- In this paper, we show that ECM, and more specifically ECM
ing tumors by avoiding the requirement for a clonal expansion remodeling through increased collagen VI expression by the
of a small number of resistant cells. Clonal expansion and field tumor cells, may contribute to drug resistance. In this regard,
effect are clearly not mutually exclusive, and both mechanisms it is particularly intriguing that COL6A3 expression in primary
may be at work during treatment of cancer patients with chemo- ovarian tumors appears correlated with tumor grade, a marker
that has been associated with ovarian cancer response to che-therapeutic drugs. Furthermore, it is likely that the drug response
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Figure 6. Collagen VI staining of human ovarian cancers
Cy-5-conjugated antibody against collagen VI was used to analyze ovarian
Figure 5. COL6A3 expression in microdissected ovarian tumors tumor sections. H&E staining for three different representative tumors (D–F)
is shown as well as the corresponding collagen VI staining (A–C). Red Cy-5A: Fold overexpression of COL6A3 compared to an ovarian surface epithe-
staining is apparent in panels (A) and (B). Tumor photographed in panellial culture is shown for ovarian tumors of various subtypes: serous, mucinous
(C) did not exhibit collagen VI staining. Collagen VI is frequently overex-(Muc), endometrioid (Endo), and clear cell (CC). ACRP (Ac), the cisplatin-
pressed in the vicinity of the cancer cells but absent in the stromal areas.resistant cell line generated in this study, is included for comparison, along
The approximate demarcations between stroma (S) and cancer (C) arewith A2780 (A), the parental line.
shown by broken lines.B: Expression levels of COL6A3 in serous ovarian tumors as a function of
tumor grade. The dotted line represents an arbitrary value emphasizing
the difference in expression levels between poorly differentiated (PD) and
moderately to well differentiated (MD  WD) ovarian serous tumors. The p
value for PD versus MD  WD is 0.018. panded (ACR1-9) along with another set, which were pooled and passaged
together (ACRP). These clones were then tested individually for resistance
to various chemotherapeutic drugs by a clonogenic assay. All the cell lines
were grown in RPMI with 10% FBS and 4 g/ml bovine insulin (Invitrogen
Life Technologies, Carlsbad, California).motherapy and overall survival. The increased drug resistance
provided by the remodeled ECM may play a role in the failure
Clonogenic assays and growth on collagenof cancer therapy. Strategies involving inhibition of ECM-tumor
Cells were counted and plated in 6-well culture dishes. The cells were
interactions or resulting signaling may therefore improve effi- allowed to recover for 16 hr and then were treated for 24 hr with the indicated
ciency of standard chemotherapy and may represent a promis- concentration of cisplatin (Sigma) or other chemotherapeutic agents (taxol
ing new approach for cancer treatment. and doxorubicin). The drug was removed and surviving cells were left to
form colonies. This protocol was found to yield more reproducible results
Experimental procedures compared to methods involving the replating of cells following drug treat-
ment. Colonies were stained with 0.25% Crystal violet/20% ethanol for 5
Generation of cisplatin-resistant cell lines min, washed with HBSS, and allowed to dry. The well images were captured
The cisplatin-sensitive serous adenocarcinoma cell line A2780 was gener- with a CCD camera and colonies were counted with the MCID M4 image
ously provided by Dr. Vilhelm Bohr. This cell line was used to generate the analysis system version 3.0 (Imaging Research, Inc., St. Catharines, Ontario).
cisplatin-resistant cell lines ACR6 and ACRP. A2780 was first treated with To study the effects of collagen, 12-well dishes were either coated with
5 M cisplatin (Sigma, St. Louis, Missouri) for 24 hr followed by a recovery 10 g of human placental collagen I or VI (Rockland Immunochemicals, Inc.,
period. The remaining colonies were trypsinized, pooled, and passaged into Gilbertsville, Pennsylvania) in 250 l of PBS or left uncoated. The different
several flasks until they were 90% confluent. The cisplatin treatment was lines were plated at a density of 4  103 cells/well. 16 hr later, the cells were
repeated twice, once with 5 M before a final exposure to 10 M cisplatin. treated for a period of 24 hr with varying concentrations of cisplatin in the
presence of 1% or 10% FBS. Cisplatin was removed, cells were washedAfter the last treatment, nine individual colonies were subcloned and ex-
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with HBSS, and surviving cells were cultivated in RPMI media containing Acknowledgments
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